Bilateral Erector Spina Block Versus Parasternal Block in Adult Heart Surgery
Ultrasound-GTrialuided Bilateral Erector Spina Block Versus Parasternal Block in Adult Cardiac Surgery: A Prospective, Randomized, Controlled Study.
1 other identifier
interventional
93
1 country
2
Brief Summary
Inadequate pain relief after cardiac surgery increases morbidity and results in a high incidence of persistent poststernotomy pain syndrome. The use of special opioid-based analgesia causes adverse effects such as nausea, vomiting, sedation, urinary retention, respiratory depression and delayed tracheal extubation. Regional anesthesia techniques such as pectoralis nerve block and serratus anterior block provide analgesia in the sternum and pain relief in the lateral / posterior chest Wall. Erector spinae (ESP) block, a new and simple myofascial block, provides wide multi-dermatomal sensory block. In the T5 spinous process, bilateral ESP block provides analgesia from T2 to T9 sensory level, resulting in both somatic and visceral analgesia by blocking both the dorsal and ventral of the spinal nerves, including the sympathetic chain. This block may provide adequate analgesia for median sternotomy because the main nerve supply to the sternal region is from T2 to T6. Median sternotomy incision and mediastinal tube regions are the major source of pain in patients undergoing cardiac surgery. The anterior and posterior branches of the intercostal nerves give nerves to the sternum. Parasternal local anesthetic infiltration around the sternum is effective in providing early postoperative analgesia and reducing opioid requirements and therefore has positive effects on healing. This simple and fast technique can be used even for anticoagulated patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2019
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 13, 2019
CompletedFirst Posted
Study publicly available on registry
September 16, 2019
CompletedStudy Start
First participant enrolled
September 17, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 14, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2022
CompletedFebruary 6, 2024
February 1, 2024
2.1 years
September 13, 2019
February 3, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Morphine consumption by PCA
Morphine consumption used in case of pain
Change from baseline 1 , 3, 6, 12 and 24 hours after extubation
Secondary Outcomes (3)
Change Pain Scores
Time Frame: 1 hour,3 hours, 6 hours, 12 hours, 24 hours after the extubation
Change Blood Gas
Change from Baseline at 60 minutes,2 hours, 4 hours, 6 hours, 12 hours, 24 hours after extübation ,
Blood Pressure
Change from Baseline at 60 minutes,2 hours, 4 hours, 6 hours, 12 hours, 24 hours after extübation ,
Study Arms (3)
Group C
NO INTERVENTIONPCA (Patient controlled analgesia) and morphine consumption will be monitored in the postoperative period.
Group ES (Erector Spina Plane)
ACTIVE COMPARATORA high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle. A dose of 0.25% bupivacaine will be injected which is shown to spread both above and below the T5 level. The same process will be implemented on the other side.
Group PS (Para Sternal Block)
ACTIVE COMPARATORBefore the wire is inserted into the sternum, the sternotomy and mediastinal tube regions will be infiltrated with a mixture of bupivacaine and saline.
Interventions
While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
Eligibility Criteria
You may qualify if:
- Male and / or female patients
- Aged 18-65 years
- Patients who will have coronary artery surgery under cardiopulmonary baypass (changing one, two and three vessels) with normal left ventricular function,
- Valve diseases with normal left ventricular function,
- ASD (Atrial Septal Defect) cases for atrial septal defect closure
- Patients with valve + CABG without left ventricular dysfunction will be included in the study.
- Ejection- Fraction\> 50-55
You may not qualify if:
- Emergency and repeat heart surgery cases
- Advanced left coronary artery disease and left ventricular dysfunction
- Receiving preoperative inotropic support therapy,
- With mitral stenosis with atrial tombus,
- With low cardiac out put syndrome,
- Need intra-aortic balloon pump during surgery,
- Bleeding and coagulation disorder,
- Liver and kidney dysfunction,
- Patients with uncontrolled diabetes mellitus and coronary artery pulmonary disease,
- Opioid, analgesic and bupivacaine allergy,
- Patients with atrial fbrilation using anticoagulants
- Patients with cognitive dysfunction
- Patients who do not want to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Kahramanmaras Sutcu Imam Univercity Faculty of edicine
Kahramanmaraş, Onikişubat, 251/A 46040, Turkey (Türkiye)
Kahramanmaras Sutcu Imam University Faculty of Medicine
Kahramanmaraş, Onikişubat, 251/A 46040, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
yavuz orak, md
Kahramanmaraş Sutcu Imam University Faculty of Medicine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
September 13, 2019
First Posted
September 16, 2019
Study Start
September 17, 2019
Primary Completion
October 14, 2021
Study Completion
May 15, 2022
Last Updated
February 6, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share